Contribution of revenue from drugs subject to price negotiation under the Inflation Reduction Act to the revenue, profit, and returns of pharmaceutical manufacturers.
- DOI
- 10.1016/j.drudis.2025.104585
- Published
- 2026 Jan
- Container
- Drug discovery today
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.drudis.2025.104585,
title = {Contribution of revenue from drugs subject to price negotiation under the Inflation Reduction Act to the revenue, profit, and returns of pharmaceutical manufacturers.},
author = {Twomey J and Kersten L and Zhou EW and Ledley FD},
year = {2026},
journal = {Drug discovery today},
doi = {10.1016/j.drudis.2025.104585},
url = {https://doi.org/10.1016/j.drudis.2025.104585}
}RIS
TY - JOUR TI - Contribution of revenue from drugs subject to price negotiation under the Inflation Reduction Act to the revenue, profit, and returns of pharmaceutical manufacturers. AU - Twomey J AU - Kersten L AU - Zhou EW AU - Ledley FD PY - 2026 JO - Drug discovery today DO - 10.1016/j.drudis.2025.104585 UR - https://doi.org/10.1016/j.drudis.2025.104585 ER -
APA
J, T., L, K., EW, Z., & FD, L. (2026). Contribution of revenue from drugs subject to price negotiation under the Inflation Reduction Act to the revenue, profit, and returns of pharmaceutical manufacturers.. Drug discovery today. https://doi.org/10.1016/j.drudis.2025.104585
Source records
- pubmed · retrieved 2026-09-26T14:29:52.841Z